Table 1.
First transplant characteristics. Data are displayed as total number (%) or median (IQR). Exact CLAD date was known in 81 BOS patients and 46 rCLAD patients. Last FEV1 and FVC was available in 91 BOS and 47 rCLAD patients. Last TLC was available for 35 BOS and 18 rCLAD patients. For calculating the percentages of patients with HLA antibodies, colonization, EGFR clearance and diabetes, the patients with unknown data were not taken into account.
| BOS | rCLAD | ||
|---|---|---|---|
| N | 94 (66%) | 49 (34%) | |
| Initial age(y) | 28 (22–42) | 33 (22–41) | 0.67 |
| Gender male, n (%) | 48 (55%) | 25 (54%) | 1.00 |
| Underlying disease, n (%) | 0.047 | ||
| CF+BRECT | 56 (60%) | 23 (48%) | |
| Emphysema/α1ATD | 15 (16%) | 4 (9%) | |
| Interstitial Lung disease | 11 (12%) | 14 (28%) | |
| Others | 12 (13%) | 8 (16%) | |
| Initial transplantation, n(%) | 0.49 | ||
| SSLTx | 80 (85%) | 44 (90%) | |
| SLTx | 5 (5%) | 4 (8%) | |
| HLTx | 5 (5%) | 1 (2%) | |
| SSLTx+liver | 3 (3%) | 0 (0%) | |
| Living lobar | 1 (1%) | 0 (0%) | |
| Time to diagnosis of CLAD (d) | 733 (414–1313) | 982 (564–1363) | 0.11 |
| Time between CLAD and re-LTx (d) | 373 (244–1033) | 341 (194–1241) | 0.30 |
| Days alive with first graft (d) | 1323 (768–2472) | 1697 (905–2472) | 0.30 |
| Best FEV1 before re-LTx (L) | 2.66 (2.20–3.19) | 2.68 (2.12–3.24) | 0.83 |
| Last FEV1 before re-LTx (L) | 0.64(0.50–0.81) | 0.75(0.60–1.00) | 0.049 |
| Last FVC before re-LTx (L) | 1.84(1.36–2.31) | 1.38(1.03–1.70) | <0.0001 |
| Last TLC before re-LTx (L) | 5.9(5.2–6.7) | 4.2(3.3–4.8) | <0.0001 |
| Last FEV1/FVC before re-LTx | 0.35(0.29–0.47) | 0.63(0.44–0.73) | <0.0001 |
| HLA antibodies before re-LTx, n(%) | 0.019 | ||
| Present | 15 (26%) | 15 (52%) | |
| Absent | 42 (74%) | 14 (48%) | |
| Unknown | 37 | 20 | |
| Diabetes before re-LTx | 0.064 | ||
| Present | 47 (51%) | 16 (34%) | |
| Absent | 46 (49%) | 31 (66%) | |
| Unknown | 1 | 2 | |
| Colonization at re-LTx | 0.20 | ||
| Present | 46 (49%) | 18 (55%) | |
| Absent | 48 (51%) | 30 (45%) | |
| Unknown | 0 | 1 | |
| EGFR clearance | 0.89 | ||
| EGFR<60 | 21 (23%) | 10 (22%) | |
| EGFR ≥60 | 71 (77%) | 36 (78%) | |
| Unknown | 2 | 3 |
Abbreviations: CF: cystic fibrosis; BRECT: bronchiectasis; α1ATD: alpha1- anti trypsin deficiency; SSLTx: sequential single lung transplantation; HLTx: Heart-lung transplantation; CLAD: chronic lung allograft dysfunction; re-LTx: Redo lung transplantation; FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity; TLC: total lung capacity